People · Operator
Named in public records as an officer, director or promoter · active 2009–2019 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| FibRx Derm, Inc. | — | Biotechnology | Series A | $4.2M | $151.8M | 2019 |
| Chromaderm, Inc. | — | Other Health Care | Seed | $3.6M | $89.2M | 2015 |
| Lotus Tissue Repair, Inc. | — | Pharmaceuticals | Seed | $2.8M | $104.6M | 2011 |
| Critical Biologics Corp | — | Biotechnology | Pre-Seed | $500K | $27.6M | 2009 |
James W. Fordyce at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James W. Fordyce on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gerald Chan | 1 | 13 |
| Mark De Souza | 1 | 10 |
| Mark P. De Souza | 1 | 7 |
| Thomas Stossel | 1 | 2 |
| Chun Chung W. Kwong | 1 | 1 |
| Karoly W. Nikolich | 1 | 1 |
| Terence W. Lam Ting Yin | 1 | 1 |
| Mark P. deSouza | 1 | 1 |
| Scott Coleridge | 1 | 1 |
| Ashleigh W. Palmer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.